Back to top

Image: Bigstock

Should You Buy CTI BioPharma (CTIC) After Golden Cross?

Read MoreHide Full Article

CTI BioPharma Corp. (CTIC - Free Report) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, CTIC's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross."

A golden cross is a technical chart pattern that can signify a potential bullish breakout. It's formed from a crossover involving a security's short-term moving average breaking above a longer-term moving average, with the most common moving averages being the 50-day and the 200-day, since bigger time periods tend to form stronger breakouts.

Golden crosses have three key stages that investors look out for. It starts with a downtrend in a stock's price that eventually bottoms out, followed by the stock's shorter moving average crossing over its longer moving average and triggering a trend reversal. The final stage is when a stock continues the upward climb to higher prices.

A golden cross is the opposite of a death cross, another technical event that indicates bearish price movement may be on the horizon.

CTIC has rallied 91.9% over the past four weeks, and the company is a #3 (Hold) on the Zacks Rank at the moment. This combination indicates CTIC could be poised for a breakout.

Once investors consider CTIC's positive earnings outlook for the current quarter, the bullish case only solidifies. No earnings estimate has gone lower in the past two months compared to 1 revisions higher, and the Zacks Consensus Estimate has increased as well.

Moving Average Chart for CTIC

Investors may want to watch CTIC for more gains in the near future given the company's key technical level and positive earnings estimate revisions.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


CTI BioPharma Corp. (CTIC) - free report >>

Published in